



#3

RECEIVED

OCT 15 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Gennady MERKULOV et al. Art Unit: 1652

TECH CENTER 1600/2900

Serial No.: 10/014,501

Examiner: C. Fronda

Filed: December 14, 2001

Atty. Docket: CL001177 DIV2

For: ISOLATED HUMAN METALLOPROTEASE PROTEINS,
NUCLEIC ACID MOLECULES ENCODING HUMAN
PROTEASE PROTEINS, AND USES THEREOF

**Statement Regarding Duty to Disclose Information Material To Patentability Under
37 CFR 1.56 (a) and (b)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants hereby notify the US Patent and Trademark Office of the documents listed on the attached PTO Form SB/08A, which may be deemed relevant to the patentability of the claims of the above application. One copy of each of the listed documents is submitted herewith. The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application.

The undersigned states that each item listed on the attached PTO Form SB/08A was first cited in a communication from a Foreign Patent Office in the above application's foreign counterpart or not known to the Undersigned for more than three months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

CELERA GENOMICS

Date: October 11, 2002

By:


Lin Sun-Hoffman, Ph.D., Reg No. 47,983

Celera Genomics Corporation
45 West Gude Drive, C2-4#20
Rockville, MD 20850
Tel: 240-453-3067
Fax: 240-453-3084

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

OCT 11 2002

The logo consists of a circular border containing the words "PATENT & TRADEMARK OFFICE" in a stylized font. A diagonal line from the top-left to the bottom-right separates the text from a rectangular area where "Exam" and "Initial" are handwritten.

U.S. PATENT DOCUMENTS

RECEIVED

OCT 15 2002

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP-901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

OCT 11 2002



Sheet 2 of 2

Complete if Known

Application Number	10/014,501
Filing Date	December 14, 2001
First Named Inventor	Gennday MERKULOV et al.
Group Art Unit	1652
Examiner Name	C Fronda
Attorney Docket Number	CL001177 DIV2

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		<p>DATABASE EMBLE 'Online! Accession No. U41767; KRATZSCHMAR, J. et al., March 23, 1996</p> <p>KRATZSCHMAR, J et al.: "Metargin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence." Journal of Biological Chemistry, vol. 271 no. 9, pages 4593-4596: March 1, 1996</p> <p>WU, E et al. "Expression of members of the novel membrane linked metalloproteinase family adam in cells derived from a range of haematological malignancies." Biochemical and Biophysical Research Communications, Academic Press Inc., Orlando, FL, US, vol. 235 no. 2, pages 437-442: June 18, 1997</p> <p>POINDEXTER, K et al. "The identification of seven metalloproteinase-disintegrins (ADAM) genes from genomic libraries" Gene, Elsevier Biomedical Press., Amsterdam, NL, vol. 237 no. 1, pages 61-70: September 3, 1999</p> <p>STONE, Ann L et al. "Structure-function analysis of the ADAM family of disintegrin-like' and metalloproteinase-containing proteins (review)." Journal of Protein Chemistry, vol. 18 no. 4, pages 447-465: May 1999</p> <p>MOSS, Marcia L et al. "TACE and other ADAM proteases as targets for drug discovery." Drug Discovery Today, vol. 6 no. 8, pages 417-426: April 15, 2001</p>	

RECEIVED
OCT 15 2002
TECH CENTER 1600/2900

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.